The Enterprise Value as of December 2024 (TTM) for BridgeBio Pharma, Inc. (BBIO) is 6.77B

According to BridgeBio Pharma, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 6.77B. This represents a change of -0.92% compared to the average of 6.83B of the last 4 quarters.

BridgeBio Pharma, Inc. (BBIO) Historical Enterprise Value (quarterly & annually)

How has BBIO Enterprise Value performed in the past?

The mean historical Enterprise Value of BridgeBio Pharma, Inc. over the last ten years is 4.41B. The current 6.77B Enterprise Value has changed 15.26% with respect to the historical average. Over the past ten years (40 quarters), BBIO's Enterprise Value was at its highest in in the June 2021 quarter at 9.96B. The Enterprise Value was at its lowest in in the June 2018 quarter at 0.

BridgeBio Pharma, Inc. (BBIO) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of BridgeBio Pharma, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BridgeBio Pharma, Inc. (BBIO) Average Enterprise Value

How has BBIO Enterprise Value performed in the past?

The current Enterprise Value of BridgeBio Pharma, Inc. (BBIO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

BridgeBio Pharma, Inc. (BBIO) Enterprise Value vs. Peers

How is BBIO’s Enterprise Value compared to its peers?

BridgeBio Pharma, Inc.’s Enterprise Value is greater than IVERIC bio, Inc. (5.13B), greater than Blueprint Medicines Corporation (6.10B), greater than Amylyx Pharmaceuticals, Inc. (206.05M), less than Karuna Therapeutics, Inc. (12.43B), greater than Day One Biopharmaceuticals, Inc. (847.99M), greater than Mirati Therapeutics, Inc. (3.91B), greater than Terns Pharmaceuticals, Inc. (225.51M), greater than Apellis Pharmaceuticals, Inc. (4.19B), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than PTC Therapeutics, Inc. (3.39B), greater than Krystal Biotech, Inc. (4.22B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Madrigal Pharmaceuticals, Inc. (6.69B), greater than Acumen Pharmaceuticals, Inc. (104.35M), greater than Inozyme Pharma, Inc. (212.37M), greater than X4 Pharmaceuticals, Inc. (76.47M),

Build a custom stock screener for BridgeBio Pharma, Inc. (BBIO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BridgeBio Pharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BridgeBio Pharma, Inc. (BBIO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BridgeBio Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.